We are live on
!
Find out more
HS
HighVista Strategies Portfolio holdings
AUM
$362M
1-Year Est. Return
230.96%
This Fund
S&P 500
This Quarter
Est. Return
-6.86%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$166M
AUM Growth
+$8.35M
(+5.3%)
Cap. Flow
+$27.8M
Cap. Flow
% of AUM
16.81%
Top 10 Holdings %
Top 10 Hldgs %
40.91%
Holding
125
New
39
Increased
43
Reduced
18
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mastercard
MA
|
+$4.42M |
| 2 |
iShares Russell 1000 Value ETF
IWD
|
+$3.73M |
| 3 |
TGNA
TEGNA Inc
TGNA
|
+$3.12M |
| 4 |
BCYC
Bicycle Therapeutics
BCYC
|
+$2.8M |
| 5 |
TWTR
Twitter, Inc.
TWTR
|
+$2.75M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PBCT
People's United Financial Inc
PBCT
|
+$3.92M |
| 2 |
Fidelity National Information Services
FIS
|
+$3.85M |
| 3 |
CERN
Cerner Corp
CERN
|
+$3.49M |
| 4 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$1.5M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$979K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.47% |
| 2 | Technology | 22.39% |
| 3 | Financials | 16.85% |
| 4 | Communication Services | 4.29% |
| 5 | Consumer Discretionary | 2.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRTX
51
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $745K | 0.45% |
11,096
+1,343
| +14% | +$85.4K |
|
52
Arcutis Biotherapeutics
ARQT
$3.26B
| $734K | 0.44% |
+34,462
| New | +$707K |
|
53
Alnylam Pharmaceuticals
ALNY
$29B
| $728K | 0.44% |
4,988
-567
| -10% | -$80.4K |
|
54
Sarepta Therapeutics
SRPT
$1.81B
| $718K | 0.43% |
9,581
-1,729
| -15% | -$127K |
|
55
BioMarin Pharmaceuticals
BMRN
$13.3B
| $712K | 0.43% |
8,596
+3,003
| +54% | +$239K |
|
56
Ascendis Pharma A/S
ASND
$16.8B
| $692K | 0.42% |
7,442
-379
| -5% | -$35.7K |
|
57
Xenon Pharmaceuticals
XENE
$6.21B
| $682K | 0.41% |
22,435
-5,557
| -20% | -$168K |
|
58
AnaptysBio
ANAB
$1.64B
| $672K | 0.41% |
33,103
+19,105
| +136% | +$423K |
|
|
TCDA
59
DELISTED
Tricida, Inc. Common Stock
TCDA
| $664K | 0.4% |
68,548
-38,654
| -36% | -$368K |
|
60
Arvinas
ARVN
$588M
| $660K | 0.4% |
+15,686
| New | +$787K |
|
|
LKFT
61
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.76B
| $658K | 0.4% |
11,801
-1,408
| -11% | -$83.5K |
|
62
Alphabet (Google) Class C
GOOG
$4.35T
| $647K | 0.39% |
+5,920
| New | +$699K |
|
63
GH Research
GHRS
$2.03B
| $638K | 0.39% |
63,936
+11,096
| +21% | +$144K |
|
|
MORF
64
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $634K | 0.38% |
29,230
+18,313
| +168% | +$511K |
|
65
Natera
NTRA
$45.9B
| $631K | 0.38% |
17,812
+4,364
| +32% | +$162K |
|
66
Crinetics Pharmaceuticals
CRNX
$8.93B
| $614K | 0.37% |
32,948
-11,278
| -26% | -$225K |
|
|
BPMC
67
DELISTED
Blueprint Medicines
BPMC
| $612K | 0.37% |
+12,108
| New | +$709K |
|
68
Vaxcyte
PCVX
$8.67B
| $609K | 0.37% |
+27,965
| New | +$647K |
|
69
Celldex Therapeutics
CLDX
$3.37B
| $604K | 0.36% |
22,412
-3,326
| -13% | -$96.6K |
|
|
HZNP
70
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $592K | 0.36% |
7,419
-837
| -10% | -$79.3K |
|
71
Acadia Pharmaceuticals
ACAD
$5.06B
| $562K | 0.34% |
39,900
+5,784
| +17% | +$108K |
|
72
Relmada Therapeutics
RLMD
$484M
| $560K | 0.34% |
29,493
+8,112
| +38% | +$177K |
|
|
ISEE
73
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $557K | 0.34% |
57,919
+4,336
| +8% | +$54.4K |
|
74
Amazon
AMZN
$3T
| $538K | 0.32% |
+5,068
| New | +$634K |
|
75
Viridian Therapeutics
VRDN
$2.61B
| $521K | 0.31% |
45,039
-4,026
| -8% | -$54.1K |
|
Similar funds
SIAG
MS
WI
WTFG
VIA
A6
PI
ACM
HighVista Strategies's Q2 2022 Portfolio in Review
As of Q2 2022, HighVista Strategies held 125 positions worth $166M, up 5.3% from $157M the previous quarter. Its ten largest holdings account for 41% of the portfolio.
HighVista Strategies deployed $27.8M of net new capital in Q2 2022, opening 39 new positions and adding to 43 existing holdings. Its largest new stake was iShares Russell 1000 Value ETF: 23,825 shares worth $3.45M.
By sector, the portfolio is most concentrated in Healthcare at 46% of assets, up from 44% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $551K trimmed.
- HighVista Strategies's largest Q2 2022 buy was iShares Russell 1000 Value ETF: 23,825 shares worth $3.45M.
- HighVista Strategies added most to Mastercard in Q2 2022, an estimated $4.42M increase.
- HighVista Strategies's biggest Q2 2022 reduction was Protagonist Therapeutics, cutting an estimated $551K.
- HighVista Strategies fully exited People's United Financial Inc in Q2 2022, selling an estimated $3.92M.
- HighVista Strategies's ten largest holdings make up 41% of its $166M portfolio in Q2 2022.
- HighVista Strategies opened 39 new positions and closed 15 in Q2 2022.
- HighVista Strategies's portfolio value rose 5.3% quarter-over-quarter to $166M.
Based on HighVista Strategies's 13F filing for Q2 2022, filed 15 Aug 2022.